• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌肝转移的手术治疗-影响疗效的因素。

Surgery for breast cancer liver metastases - factors determining results.

机构信息

Professor of Surgery, Department of Surgery, University Hospital, Faculty of Medicine, Alej Svobody 80, 304 60 Pilsen, Czech Republic.

出版信息

Anticancer Res. 2014 Mar;34(3):1281-6.

PMID:24596373
Abstract

BACKGROUND/AIM: The results of the surgical treatment of liver metastases from breast cancer (BCLMs) may be determined by various factors. The aim of the present study was to specify the risk factors for surgical treatment of BCLM.

PATIENTS AND METHODS

Twenty-four female patients with BCLMs were treated with liver resection or radiofrequency ablation (RFA). We evaluated the effects of patient age, time interval between the breast cancer and BCLM surgery, the type of surgical procedure, histopathological findings of the primary tumor, the number and overall diameter of BCLMs, the presence of resectable extra-hepatic metastases, and local tumor recurrence after breast cancer surgery on patients' overall (OS) and progression-free survival (PFS).

RESULTS

Age <50 years and shorter interval between breast and liver surgery were risk factors for poorer OS (p<0.02 and p<0.01, respectively) and for PFS (p<0.01 and p<0.01, respectively). The presence of extra-hepatic metastases was a risk factor for OS (p<0.005). An overall diameter of BCLM ≥3.5 cm and a negative status of both estrogen (ER) and progesterone receptors (PR) in the primary tumor were risk factors for poorer PFS (p<0.009 and p<0.0003, respectively).

CONCLUSION

The risk factors for surgery for BCLMs are age <50 years, the presence of extra-hepatic metastases, hormone receptor negativity of the primary tumor and an overall BCLM diameter ≥3.5 cm.

摘要

背景/目的:乳腺癌肝转移(BCLM)的手术治疗结果可能由多种因素决定。本研究旨在明确影响 BCLM 手术治疗的危险因素。

患者与方法

对 24 例接受肝切除术或射频消融术(RFA)治疗的 BCLM 女性患者进行评估。我们评估了患者年龄、乳腺癌与 BCLM 手术之间的时间间隔、手术类型、原发肿瘤的组织病理学发现、BCLM 的数量和总直径、可切除的肝外转移灶的存在以及乳腺癌手术后局部肿瘤复发对患者总生存(OS)和无进展生存(PFS)的影响。

结果

年龄<50 岁和乳腺癌与肝手术之间的时间间隔较短是 OS(p<0.02 和 p<0.01)和 PFS(p<0.01 和 p<0.01)较差的危险因素。肝外转移的存在是 OS(p<0.005)的危险因素。BCLM 的总直径≥3.5 cm 和原发肿瘤中雌激素(ER)和孕激素受体(PR)均阴性是 PFS 较差的危险因素(p<0.009 和 p<0.0003)。

结论

BCLM 手术的危险因素是年龄<50 岁、存在肝外转移、原发肿瘤激素受体阴性和 BCLM 总直径≥3.5 cm。

相似文献

1
Surgery for breast cancer liver metastases - factors determining results.乳腺癌肝转移的手术治疗-影响疗效的因素。
Anticancer Res. 2014 Mar;34(3):1281-6.
2
[Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].腹股沟淋巴结转移乳腺癌患者的临床病理特征及预后因素:附17例报告
Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):207-11. doi: 10.3760/cma.j.issn.0253-3766.2013.03.010.
3
[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].[雌激素受体、孕激素受体及人表皮生长因子受体-2在接受乳房切除术的淋巴结阳性乳腺癌患者中的预后价值]
Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5.
4
Prognostic factors for longer disease free survival and overall survival after surgical resection of isolated liver metastasis from breast cancer.乳腺癌孤立性肝转移手术切除后更长无病生存期和总生存期的预后因素。
J BUON. 2013 Oct-Dec;18(4):859-65.
5
Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes.乳腺癌肝转移的肝切除术:内在亚型的影响。
Eur J Surg Oncol. 2020 Sep;46(9):1588-1595. doi: 10.1016/j.ejso.2020.03.214. Epub 2020 Mar 28.
6
Repeat Hepatectomy for Breast Cancer Liver Metastases.乳腺癌肝转移的重复肝切除术
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1057-66. doi: 10.1245/s10434-015-4785-8. Epub 2015 Aug 11.
7
Role of surgical treatment in breast cancer liver metastases: a single center experience.手术治疗在乳腺癌肝转移中的作用:单中心经验
Anticancer Res. 2014 Oct;34(10):5563-8.
8
Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery.根治性手术后结直肠癌异时性肝转移的射频消融治疗
Ann Surg Oncol. 2008 Jan;15(1):227-32. doi: 10.1245/s10434-007-9625-z. Epub 2007 Sep 20.
9
[Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].[晚期三阴性乳腺癌患者的治疗结果及临床病理特征]
Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):381-4.
10
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor.IV期乳腺癌且原发肿瘤完整患者的原发肿瘤切除效果
Ann Surg Oncol. 2006 Jun;13(6):776-82. doi: 10.1245/ASO.2006.03.033. Epub 2006 Apr 17.

引用本文的文献

1
Does Hepatic Metastasectomy for Breast Cancer Oligo-Metastasis to the Liver Offer Survival Advantage? Systematic Review and Meta-Analysis.乳腺癌肝寡转移行肝转移灶切除术是否能带来生存获益?系统评价与Meta分析。
J West Afr Coll Surg. 2025 Apr-Jun;15(2):129-135. doi: 10.4103/jwas.jwas_16_24. Epub 2024 Sep 2.
2
Enhancing Anti-PD-1 Immunotherapy by Targeting MDSCs via Hepatic Arterial Infusion in Breast Cancer Liver Metastases.通过肝动脉灌注靶向髓源性抑制细胞增强乳腺癌肝转移中的抗PD-1免疫疗法。
Cancers (Basel). 2024 Nov 3;16(21):3711. doi: 10.3390/cancers16213711.
3
Web-Based Dynamic Nomograms for Predicting Overall Survival and Cancer-Specific Survival in Breast Cancer Patients with Lung Metastases.
用于预测伴有肺转移的乳腺癌患者总生存期和癌症特异性生存期的基于网络的动态列线图
J Pers Med. 2022 Dec 26;13(1):43. doi: 10.3390/jpm13010043.
4
Prognostic Factors in Patients with Breast Cancer Liver Metastases Undergoing Liver Resection: Systematic Review and Meta-Analysis.接受肝切除的乳腺癌肝转移患者的预后因素:系统评价和荟萃分析
Cancers (Basel). 2022 Mar 26;14(7):1691. doi: 10.3390/cancers14071691.
5
Surgical therapy for breast cancer liver metastases.乳腺癌肝转移的手术治疗
Transl Cancer Res. 2020 Aug;9(8):5053-5062. doi: 10.21037/tcr-20-1598.
6
Survival Benefit of Surgical Treatment Added Into Systemic Treatment for Isolated Breast Cancer Liver Metastases: A Systematic Review and Meta-Analysis.手术治疗加全身治疗对孤立性乳腺癌肝转移的生存获益:一项系统评价和荟萃分析。
Front Surg. 2021 Oct 25;8:751906. doi: 10.3389/fsurg.2021.751906. eCollection 2021.
7
A Nomogram for Predicting Survival in Patients With Breast Cancer Liver Metastasis: A Population-Based Study.预测乳腺癌肝转移患者生存情况的列线图:一项基于人群的研究
Front Oncol. 2021 Jun 2;11:600768. doi: 10.3389/fonc.2021.600768. eCollection 2021.
8
Hepatectomy, RFA, and Other Liver Directed Therapies for Treatment of Breast Cancer Liver Metastasis: A Systematic Review.肝切除术、射频消融术及其他肝脏定向治疗用于乳腺癌肝转移的治疗:一项系统评价
Front Oncol. 2021 Mar 26;11:643383. doi: 10.3389/fonc.2021.643383. eCollection 2021.
9
Renewed considerations on the utility (or the futility) of hepatic resections for breast cancer liver metastases.对乳腺癌肝转移行肝切除术的效用(或无效性)的重新思考。
Hepatobiliary Surg Nutr. 2021 Jan;10(1):49-58. doi: 10.21037/hbsn.2019.07.12.
10
Prognostic Factors After Surgical Treatment of Liver Metastases from Breast Cancer - 19 Years of Experience.乳腺癌肝转移手术后的预后因素 - 19 年的经验。
In Vivo. 2021 Jan-Feb;35(1):417-422. doi: 10.21873/invivo.12273.